Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 06, 2021 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum

CRANBURY, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
March 10, 2021 16:31 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

CRANBURY, N.J., March 10, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
March 03, 2021 16:01 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Initiated Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationPC14586 granted Fast Track...
February 23, 2021 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces Participation at the Cowen 41st Annual Health Care Conference

CRANBURY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
February 16, 2021 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

CRANBURY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
November 24, 2020 17:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
November 23, 2020 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53

PC14586 targets p53 Y220C mutants to selectively reactivate p53, restoring the protein’s tumor-suppressing functionPhase 1/2 study is enrolling patients with advanced solid tumors that have a p53...
November 13, 2020 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights

U.S. Food and Drug Administration (FDA) clearance of PMV Pharmaceutical’s investigational new drug application for its lead product candidate PC14586PMV Pharma lead product candidate PC14586 granted...
October 13, 2020 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

CRANBURY, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
September 29, 2020 16:05 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

CRANBURY, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right